Free tool
FAERS Monitor: Creon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020725 or its brand name (Creon, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.
Reports
38,797
Serious
28,976
75% of reports
Hospitalization
14,677
Death reported
3,888
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea3,834
- death2,040
- nausea1,890
- weight decreased1,856
- fatigue1,660
- abdominal pain1,572
- vomiting1,475
- pain1,338
- abdominal pain upper1,311
- pancreatic carcinoma1,295
- infective pulmonary exacerbation of cystic fibrosis1,238
- drug ineffective1,209
- malaise1,189
- dyspnoea1,188
- off label use1,170
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 105 |
| 2005 | 94 |
| 2006 | 99 |
| 2007 | 86 |
| 2008 | 127 |
| 2009 | 191 |
| 2010 | 290 |
| 2011 | 380 |
| 2012 | 498 |
| 2013 | 686 |
| 2014 | 958 |
| 2015 | 1,365 |
| 2016 | 1,772 |
| 2017 | 1,795 |
| 2018 | 2,451 |
| 2019 | 3,620 |
| 2020 | 3,401 |
| 2021 | 2,446 |
| 2022 | 2,749 |
| 2023 | 2,591 |
| 2024 | 3,627 |
| 2025 | 5,350 |
| 2026 | 4,115 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,015,362 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 1,238 | 159.3 | 149.6 | 150,394 |
| pancreatic carcinomaSignal | 1,295 | 25.4 | 24.0 | 29,014 |
| abdominal painSignal | 1,572 | 3.7 | 3.5 | 3,081 |
| weight decreasedSignal | 1,856 | 3.6 | 3.5 | 3,543 |
| abdominal pain upperSignal | 1,311 | 3.5 | 3.3 | 2,308 |
| diarrhoeaSignal | 3,834 | 3.2 | 3.1 | 6,063 |
| vomiting | 1,475 | 1.7 | 1.6 | 436 |
| malaise | 1,189 | 1.5 | 1.4 | 182 |
| nausea | 1,890 | 1.3 | 1.2 | 132 |
| death | 2,040 | 1.3 | 1.2 | 133 |
| pain | 1,338 | 1.2 | 1.1 | 38 |
| fatigue | 1,660 | 1.2 | 1.1 | 36 |
| dyspnoea | 1,188 | 1.1 | 1.1 | 20 |
| off label use | 1,170 | 0.7 | 0.7 | 128 |
| drug ineffective | 1,209 | 0.5 | 0.5 | 656 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.